Wet Age-Related Macular Degeneration

Genentech and Roche initiated a phase 3 clinical trial to investigate the Port Delivery System with ranibizumab to treat patients with diabetic macular edema, according to a press release.

Adverum Biotechnologies will change how patients receive steroids to manage inflammation in the third and fourth cohorts of its phase 1 OPTIC trial, the company announced in a press release.

The top retina-related stories on Healio.com/OSN in 2019 included trial results, meeting coverage and FDA approvals.

Patient enrollment has been completed in two phase 3 trials of faricimab for wet age-related macular degeneration, according to communication from Genentech.

Beovu has received a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency, Novartis announced in a press release.

SAN FRANCISCO — RGX-314 gene therapy demonstrated meaningful reductions in anti-VEGF injections and increases in visual acuity and central retinal thickness among patients with wet age-related macular degeneration, according to an update presented at Retina Subspecialty Day at the American Academy of Ophthalmology annual meeting.

SAN FRANCISCO —Twice daily dosing of oral AKST4290 over the course of 6 weeks improved visual acuity in patients with neovascular age-related macular degeneration, according to a presenter at the American Academy of Ophthalmology annual meeting.

SAN FRANCISCO — In the OPTIC trial, patients with wet age-related macular degeneration who were treated with ADVM-022, an intravitreal gene therapy, did not require additional injections following treatment, according to a presenter at the American Academy of Ophthalmology annual meeting.

The Asia-Pacific Academy of Ophthalmology would like to thank all member societies that participated in this important event organized by the APAO Public Education Standing Committee. Special thanks go to the two subspecialty member societies, the Asia Cornea Society and the Asia-Pacific Vitreo-retina Society, for providing public educational materials for all APAO member societies to use.

SAN FRANCISCO — Treatment with Beovu resulted in visual acuity letter gains among patients with age-related macular degeneration and polypoidal choroidal vasculopathy, according to a presentation at Retina Subspecialty Day at the American Academy of Ophthalmology annual meeting. “Most of you have heard that in the last week, Beovu (brolucizumab, Novartis) was approved by the FDA to treat neovascular AMD,” Glenn J. Jaffe, MD, Robert Machemer Professor of Ophthalmology and Chief of the Vitreoretinal Division at Duke Eye Center, said during his presentation. “We know from clinical trials that it is effective for typical AMD.”